Maximus vs Novi

Recorded prices, access and terms.

Decision table

The entries below are recorded provider statements unless a regulatory source is linked. A provider webpage does not independently verify its licenses or quality. Maximus source · Novi source.

CompareMaximusNovi
Recorded medication/program subtotalMonthly-plan rate unconfirmed. Advertised headline prices may require prepayment, a specific dose or introductory terms. Full required cost is unconfirmed.Monthly-plan rate unconfirmed. Advertised headline prices may require prepayment, a specific dose or introductory terms. Full required cost is unconfirmed.
Full required monthly costUnconfirmed: consultation, labs, membership, dose changes and shipping must be checkedUnconfirmed: consultation, labs, membership, dose changes and shipping must be checked
Drug type listedCompoundedBrand-name and compounded
Consultation$28-35 per visit in the record; current conditions unconfirmedIncluded in the record; current conditions unconfirmed
Pharmacy licenseNot independently verified. Obtain the dispensing pharmacy name and verify its state license.Not independently verified. Obtain the dispensing pharmacy name and verify its state license.
Reported states50; confirm eligibility and clinician licensing in your state45; confirm eligibility and clinician licensing in your state
CancellationCancellation reported; notice, minimum term and refund conditions unconfirmedCancellation reported; notice, minimum term and refund conditions unconfirmed
Clinician/support as reportedLicensed physicians, lab testing availableLicensed physicians, unlimited access, nutritionist meal plans
Recorded provider checkNo date recordedNo date recorded

Which should you choose?

Ask each provider for the full cost at your prescribed dose, required labs and visits, the dispensing pharmacy, the clinician's state license, renewal charges and written refund terms. Compare those answers with your clinician.

Compounded drugs are not FDA-approved and do not undergo FDA review for safety, effectiveness or quality before marketing. FDA source and recommendations.

Maximus: evidence and terms

Recorded FDA letter (2026-06-08): Cited by FDA for false or misleading claims / misbranding in its telehealth marketing of compounded GLP-1 products. One of fifteen telehealth firms warned the same day. FDA letter.

Read Maximus's sourced record · Maximus source

Novi: evidence and terms

Read Novi's sourced record · Novi source

Compare the full provider directory · Compare recorded price subtotals

Compare providersVisit Embody →